The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients

Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets. Researchers say better long-term support is needed and warn that low-cost compounded versions may carry serious safety risks.

Raccontata dazerohedge.comsciencedaily.com